Weight Loss as Therapy for Heart Failure With Preserved Ejection Fraction

NCT ID: NCT02911337

Last Updated: 2025-07-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-31

Study Completion Date

2018-12-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine the efficacy of an intensive, supervised, lifestyle modification program on symptoms and signs of heart failure as well as laboratory and echocardiographic measures of cardiac structure and function. This will be a 6 month trial in 50 patients with a clinical diagnosis of heart failure with preserved ejection fraction (HFpEF). Patients will be enrolled in the Medical University of South Carolina weight management 15 week lifestyle change program which will involve weekly visits that rotate among the clinical specialities (dietary, exercise and behavioral) and scheduled visits with the research Registered Nurse. Each patients baseline data will be used as the control and compared with the same measurements at the 6 month end point.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure, Diastolic Weight Loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lifestyle modification

Lifestyle modification

Group Type EXPERIMENTAL

lifestyle modification

Intervention Type DIETARY_SUPPLEMENT

Subjects will be given meal replacements (shakes and bars) to be consumed twice per day for 8 weeks, and then once per day for an additional 3 weeks, and then transitioned to a structured diet.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

lifestyle modification

Subjects will be given meal replacements (shakes and bars) to be consumed twice per day for 8 weeks, and then once per day for an additional 3 weeks, and then transitioned to a structured diet.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI \> 30
* Able to perform 6 minute hall walk test
* Left Ventricular ejection fraction \>45%
* Diagnosis of heart failure with preserved ejection fraction (HFpEF) ; confirmation of HFpEF based on 1 major or 3 minor criteria listed below.

Major:

1. Elevated BNP \>200
2. cardiogenic pulmonary edema
3. Pulmonary capillary wedge pressure at rest \>15 mmhg or with exercise \>25 mmhg using invasive right heart pressure measurement

Minor:

1. Left atrial enlargement (volume \>68 ml)
2. increased left ventricular wall thickness (\>1.1cm) by echocardiography
3. E/e' \>15
4. intermediate level of BNP, 60-199

Exclusion Criteria

* uncontrolled blood pressure
* severe chronic obstructive pulmonary disease (oxygen or steroid dependent)
* recurrent major depression. presence or history of suicide behavior, and current substantial depressive symptoms. Antidepressant drugs are allowed if the dose has been stable for 3 months
* other major psychiatric illness (schizophrenia, bipolar, dementia)
* significant hepatic dysfunction
* untreated hypothyroidism or hyperthyroidism
* history of drug or alcohol abuse or dependency within the past 12 months
* acute coronary syndrome without revascularization in the past 12 months
* acute coronary syndrome with revascularization in the past 6 months
* Cerebrovascular accident or transient ischemic attack in the past 6 months
* cancer or terminal illness with life expectancy \< 3 years
* history of medical noncompliance
* significant anemia (hgb \<9)
* life threatening or uncontrolled arrhythmia
* hemodynamically relevant valvular heart disease
* infiltrative heart disease including cardiac amyloidosis, sarcoidosis, Fabry's disease
* genetic hypertrophic cardiomyopathy
* significant pericardial disease
* clinically relevant neuromuscular disease
* pregnant or may become pregnant in the next 6 months
* prior major organ transplant or intent to transplant ( on the transplant list)
* pacemaker dependant
* clinically significant congenital heart disease that may be cause of symptoms
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical University of South Carolina

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

MUSC Gazes Research Institue

Charleston, South Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

El Hajj EC, El Hajj MC, Sykes B, Lamicq M, Zile MR, Malcolm R, O'Neil PM, Litwin SE. Pragmatic Weight Management Program for Patients With Obesity and Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2021 Nov 2;10(21):e022930. doi: 10.1161/JAHA.121.022930. Epub 2021 Oct 29.

Reference Type DERIVED
PMID: 34713711 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

WTLSSCHF

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

DASH Diet in Heart Failure Outpatients
NCT05117086 ACTIVE_NOT_RECRUITING NA
The Use of Advanced Imaging in HFpEF
NCT06905405 NOT_YET_RECRUITING